Anonymous
Guest
Anonymous
Guest
Saw the article I am not buying it are you.
They might have 3000 forms but that's far from 3000 Rx. Remember some will never start and others will get financial assistance. Who cares what they get!
Yes, Clearly not a threat. Someone fire this guy for his stupidity.
Yes, Clearly not a threat. Someone fire this guy for his stupidity.
I'm in a large academic city with one of the highest amount of scripts showing for a total of 5
worst launch i have ever seen - huge demand for an oral and barely being used 3 months in - more layoffs at novartis are coming!
4300 RX's half come from Biogen in just 3 months. Yes its slow to get them on but they will get on. Say good bye to killsabri and Avonex was losing share even before Gilenya.
Take a common sense approach. The risk of PML using Tysabri has doubled since two year plus data has become available. Researchers have stated that a negative test to the JCV virus doesn't guarantee you won't get PML. Along comes an oral drug which eliminates the need for monthly infusions.
Now if you are a newly diagnosed MS patient or the ABCR drugs aren't cutting it for you anymore, what choice would you likely make?
Uh, if you are a newly diagnosed patient and told a/b/c/r no deaths in 20 years vs gilenya 2 deaths in 1700 patients in the trials and by the way pml and tysabri was only found out after the launch, which would you take?